Non-Hodgins lymphoma treatment approved
Israel’s Teva has received US FDA approval for its Truxima treatment for several conditions of the deadly non-Hodgkin’s lymphoma, a type of blood cancer. Truxima is a bio-similar (tested low-cost alternative) to Rituxan (Rituximab) manufactured by Roche.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink